News & Updates

Show Multimedia Only

Inhaled mebufotenin shows promise in treatment-resistant depression

12 Apr 2026

Single-day treatment with GH001, a synthetic formulation of inhaled mebufotenin, has been shown to be well tolerated and yield substantial improvements in depressive symptoms in patients with treatment-resistant depression in a phase IIb trial.

Inhaled mebufotenin shows promise in treatment-resistant depression

12 Apr 2026

No link between methylphenidate use and psychosis risk among children with ADHD

10 Apr 2026

The use of methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder (ADHD) does not contribute to an increased risk of nonaffective psychosis and may even confer protection against the risk, according to a study.

No link between methylphenidate use and psychosis risk among children with ADHD

10 Apr 2026

HK-Chinese model predicts 10-year ASCVD risk in patients with schizophrenia-spectrum disorders

10 Apr 2026 by

A Hong Kong–Chinese (HK-Chinese) model achieves satisfactory accuracy in predicting 10-year atherosclerotic cardiovascular disease (ASCVD) risk in Chinese patients with schizophrenia-spectrum disorders, according to a population-based cohort study.

HK-Chinese model predicts 10-year ASCVD risk in patients with schizophrenia-spectrum disorders

10 Apr 2026

Varenicline shows promise in vaping cessation

09 Apr 2026 by

People who wish to quit vaping may find success with the help of varenicline, which has been found in a recent study to result in numerically higher abstinence rates relative to placebo.

Varenicline shows promise in vaping cessation

09 Apr 2026

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

07 Apr 2026 by

Initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a lower risk of developing various incident substance use disorders (SUDs), suggests a study involving US veterans with type 2 diabetes (T2D). Its use also protects against adverse clinical outcome in people with pre-existing SUDs.

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

07 Apr 2026

Overwork stirs depressive, anxiety symptoms in migrant workers

31 Mar 2026 by

High resilience appears protective against the development of depressive and anxiety symptoms among migrant workers (MWs) and migrant domestic workers (MDWs) in Singapore, suggests a study.

Overwork stirs depressive, anxiety symptoms in migrant workers

31 Mar 2026

Antiobesity drugs plus behavioural treatment induces more weight loss than medication alone

27 Mar 2026

Oral antiobesity medications (AOMs) combined with behavioural treatment via telemedicine induces greater weight loss than medications alone, a study has shown.

Antiobesity drugs plus behavioural treatment induces more weight loss than medication alone

27 Mar 2026

Clozapine shows promise as second-line antipsychotic therapy

26 Mar 2026

In patients with first-episode psychosis who did not respond to initial antipsychotic treatment, the use of clozapine appears to improve clinical outcomes better than olanzapine and amisulpride, according to a study.

Clozapine shows promise as second-line antipsychotic therapy

26 Mar 2026

Healthcare environments remain unsafe for trans, gender-diverse people

25 Mar 2026 by

Transgender and gender-diverse (TGD) individuals are at the receiving end of inequities in psychological well-being and quality of life (QoL), driven in part by minority stress and discrimination, reveals a study.

Healthcare environments remain unsafe for trans, gender-diverse people

25 Mar 2026

Academic pressure contributes to depression in teens

25 Mar 2026

Academic pressure may be putting adolescents at risk of depressive symptoms and, possibly, self-harm, according to new research.

Academic pressure contributes to depression in teens

25 Mar 2026

News & Updates

Showing Psychiatry articles

Showing

Specialty:

Inhaled mebufotenin shows promise in treatment-resistant depression

Inhaled mebufotenin shows promise in treatment-resistant depression

No link between methylphenidate use and psychosis risk among children with ADHD

No link between methylphenidate use and psychosis risk among children with ADHD

HK-Chinese model predicts 10-year ASCVD risk in patients with schizophrenia-spectrum disorders

HK-Chinese model predicts 10-year ASCVD risk in patients with schizophrenia-spectrum disorders

Varenicline shows promise in vaping cessation

Varenicline shows promise in vaping cessation

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

Overwork stirs depressive, anxiety symptoms in migrant workers

Overwork stirs depressive, anxiety symptoms in migrant workers

Antiobesity drugs plus behavioural treatment induces more weight loss than medication alone

Antiobesity drugs plus behavioural treatment induces more weight loss than medication alone

Clozapine shows promise as second-line antipsychotic therapy

Clozapine shows promise as second-line antipsychotic therapy

Healthcare environments remain unsafe for trans, gender-diverse people

Healthcare environments remain unsafe for trans, gender-diverse people

Academic pressure contributes to depression in teens

Academic pressure contributes to depression in teens